ddwn... Exactly what I was thinking when I looked at the...

ddwn... Exactly what I was thinking when I looked at the shortman website this morning. The shorts must have thought they were on to a good thing until they read MSB is in "advanced and active discussions" with regards to global licensing deals with a number global commercialisation partners (plural) for both CHF & CLBP ( yes, I appreciate the company has alluded to discussions in the past but this seems to be a step up in emphasis to most commentators).With the Biotech conference in San Francisco only a week away it would not be beyond the realms of possibility that they are getting close to agreeing Head of Terms on at least one blockbuster product at that conference . With all the major pharmas headed to the West Coast...my blood pressure is starting to rise. I would hate to have a big short position now. Try buying back 38m shares in a few days if the Company announces a mega licensing deal. A deal may well stipulate that FDA approval is a condition of any significant milestone payment ...but payments of between $250-400m would not be out of the question combined with double digit royalties considering the size of the addressable markets for each treatment.

Regarding aGVHD, I have also noticed from other biotech stocks, that shares often rise on submission of a BLA because most of the real work with the FDA is considered to take place before the application is made. I have already mentioned, the over 80% average success rates for BLA applications, in a previous post. Remestemcel-l is being submitted in the 1Q 19 . 

All aboard.